JeffreyGlennMD
Gastroenterology • Stanford, CAAssociate Professor, Medicine - Gastroenterology & Hepatology, Stanford University Medical Center
Dr. Glenn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Gastroenterology, 1995 - 1998- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1993 - 1996
University of California San Francisco School of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1994 - 2026- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive Start of enrollment: 2009 Jul 01
Publications & Presentations
PubMed
- 6 citationsHDV RNA assays: Performance characteristics, clinical utility, and challenges.Heiner Wedemeyer, Mitchell Leus, Thomas R Battersby, Jeffrey Glenn, Emmanuel Gordien
Hepatology. 2025-02-01 - Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice.Sarah Duehren, Takuro Uchida, Masataka Tsuge, Nobuhiko Hiraga, Susan L Uprichard
Virus Research. 2024-11-01 - 3 citationsEstimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta-analysis.Robert J Wong, Carol Brosgart, Steven S Wong, Jordan Feld, Jeffrey Glenn
Liver International. 2024-07-01
Press Mentions
Pegylated Interferon Lambda May Prevent Severe COVID-19February 13th, 2023- New Injected Drug May Prevent Severe COVIDFebruary 9th, 2023
- The Prognosis for TelehealthMay 23rd, 2022
Grant Support
- The Pip2-Virus Interface And PI 4-Kinase: Novel Biology And Validation TargetsNational Institute Of Allergy And Infectious Diseases2012
- HCV NS4B: Translating Molecular Virology Into Novel Antiviral TherapiesNational Institute Of Allergy And Infectious Diseases2010–2012
- Advancing Clemizole For Hepatitis C: Towards A Pre-Ind PackageNational Institute Of Allergy And Infectious Diseases2010
- Towards The Creation Of Hcv-Resistant Liver Cells For TransplantationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
- HCV Ns5a: Molecular Virology And Antiviral TargetNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2010
- Novel Antiviral Targets In Hepatitis C Virus NS4BNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
